You should know very well that Ph3 and EU submission were two separate things. Phase 3 trial to see how AXAL works as the adjuvant therapy, while Phase 2 was completed as a late stage cancer drug. EU submission was based on Ph2 data plus some other older data. The management decided the data was sufficient to get a conditional approval in EU. Wrong. They should have known that, and they had no clue. Reckless and incompetent. Wasted a lot of time, resources and cash on nothing burger.
and who was in charge and ultimately responsible to get it done the proper way ? - the great useless Robert Petit who was drawing a nice fat salary and had bonus for his futile efforts at ADXS, (to add insult to injury to shareholders).
News 
Market Data 
Discover 
